دورية أكاديمية
Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
| العنوان: | Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient |
|---|---|
| المؤلفون: | Eleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I. |
| المصدر: | Journal of Immunotherapy ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380dTest |
| سنة النشر: | 2021 |
| المجموعة: | University of Thessaly Institutional Repository / Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας |
| مصطلحات موضوعية: | hepatitis B surface antigen, nivolumab, recombinant hepatitis B vaccine, hepatitis B antibody, hepatitis B vaccine, PDCD1 protein, human, programmed death 1 receptor, adult, antigen blood level, Article, cancer immunotherapy, case report, clinical article, disease predisposition, drug tolerability, electrochemiluminescence, follow up, hemodialysis patient, hepatitis B, humoral immunity, kidney hypoplasia, lung metastasis, lung nodule, male, memory cell, middle aged, nephrectomy, plasma cell, priority journal |
| الوصف: | Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 15249557 |
| العلاقة: | http://hdl.handle.net/11615/71340Test |
| DOI: | 10.1097/CJI.0000000000000365 |
| الإتاحة: | https://doi.org/10.1097/CJI.0000000000000365Test http://hdl.handle.net/11615/71340Test |
| رقم الانضمام: | edsbas.EDAEBE7F |
| قاعدة البيانات: | BASE |
| تدمد: | 15249557 |
|---|---|
| DOI: | 10.1097/CJI.0000000000000365 |